[Micrometastatic disease and residual axillary disease. Breast cancer as an example Alct].
The knowledge of the axillary involvement is a major prognosis factor for breast cancer and an important parameter for treatment decision. Nevertheless, two recent current medical situations have occurred in breast cancer, changing our management. First, with the development of mass screening and sentinel lymph nodes biopsies, we have to take treatment decisions based upon minimal lymph node involvement, with a clinical significance still poorly understood. Second, for the large tumors, potentially with lymph node involvement, we have to deal with tumor and lymph node under staging, after induction chemotherapy. We have to learn how to evaluate accurately those new parameters to treat the best way our patients.
Penault-Llorca
F
F
Département de Pathologie, Centre Jean-Perrin, 58, Rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 01, France. fpenault@cjp.fr
Mishellany
F
F
D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008403:Mass Screening; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D018365:Neoplasm, Residual / Q000473:pathology* / Q000628:therapy; D020133:Reverse Transcriptase Polymerase Chain Reaction; D021701:Sentinel Lymph Node Biopsy